L’Oréal R&I Brazil and IDOR (Instituto D’Or de Pesquisa e Ensino, Rio de Janeiro) have signed a scientific collaboration in the field of tissue engineering and more specifically skin reconstruction.

For more than 25 years, L’Oréal has been committed to developing predictive methods to evaluate the efficacy and the safety of its ingredients.

“Skin reconstruction is a great tool for developing predictive methods for products safety matters,”

explains the French beauty giant.

L’Oréal has already participated in validating several of these methods in Europe, where tests on animals are prohibited for cosmetic products, and continues to share these developments in countries where regulations are changing in favour of developing alternatives to animal testing, like in Brazil.

“The availability of these validated models in Brazil in the future will provide a valuable tool for the local scientific community in the fields of biomedical research and toxicology evaluation,”

adds L’Oréal.

Since 2012, L’Oréal and IDOR – a not-for-profit institution that aims at promoting scientific and technological advances in health – have been working together to explore cell culture and stem cell biology and recently they broadened their research scope to tissue engineering and human skin reconstruction.

“Our scientific collaboration with IDOR, especially with Pr. Stevens Rehen, illustrates our commitment to predictive evaluation. It will open up new possibilities in tissue engineering, to combine 3D biological models with microfluidic technology. Because IDOR has the necessary skills and equipment to help our Brazilian research center in this area,“

adds Blaise Didillon, Director of Research & Innovation at L’Oréal Brazil.

Dr Jorge Moll Neto, Chairman of IDOR, said he is convinced that

“this partnership with L’Oréal will lead to great developments in Brazil in strategic areas such as regenerative medicine and human tissue biology.“

More information:

From safety to efficacy: in vitro methods are becoming essential to the cosmetics industry
New cell-based tests promise alternative to animal testing